Axial Biotherapeutics Presents Preclinical Data on Microbiome – Derived Metabolites Associated with Autism Spectrum Disorder at the Society for Neuroscience 2019 Annual Meeting

WALTHAM, Mass., October 18, 2019 – Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that Dr. Torsten Madsen, acting Chief Medical Officer will be presenting preclinical data highlighting the strong association between bacteria-derived metabolites and autism spectrum disorder (ASD) at the Society for Neuroscience 2019 Annual Meeting on Saturday, October 19, 2019 in Chicago, IL.

“We are pleased to share these preclinical data, which further validate our scientific rationale and approach to treat ASD. Understanding the association between sustained levels of metabolites in systemic circulation and core and non-core behavioral symptoms associated with ASD is an important advance,” said David Donabedian, Ph.D., and Co-founder and Chief Executive Officer of Axial Biotherapeutics. “Based on these data, we believe that our approach, i.e., that modulation of bacteria-derived metabolites may represent an important new treatment paradigm for the core and non-core symptoms of ASD.”

Axial Biotherapeutics is currently investigating AB-2004, a first-in-class, therapeutic that removes metabolites in the gastrointestinal (GI) tract, in a Phase 1/2a safety and tolerability study.

Presentation Details:

  • Presentation Title: “Microbiome derived metabolites associated with autism spectrum disorder negatively impact multiple aspects of neuronal development and functionality”
  • Presenter: Torsten Madsen, MD, PhD
  • Poster Presentation: #030.08, Saturday, October 18, 2019, 1:00 PM CT

About Axial Therapeutics

Axial Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurological diseases. Axial is advancing a pipeline of small molecule product candidates with lead clinical programs that address underlying pathology and resulting symptoms in Autism Spectrum Disorder (ASD) and Parkinson’s Disease (PD), and additional preclinical initiatives in small molecules in other areas of autism and PD, as well as oncology and rare CNS diseases.

Contacts for Axial Therapeutics


Mike Beyer
Sam Brown, Inc.


Jeffrey Young, CFO